TARGIT - IORT
Intrabeam TARGIT IORT is targeted intraoperative radiotherapy treatment for breast cancer. Conceived in the UK more than 20 years ago, thoroughly tested in clinical trials, TARGIT IORT treatment is widely used to treat breast cancer patients across the world.
“The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment [lumpectomy and radiation therapy] at the time of her operation, with lower toxicity.” Lancet 2014;383:603-613
Please visit the dedicated website for TARGIT-IORT
Special relevance of TARGIT-IORT during the COVID-19 pandemic
TARGIT-IORT is given as a single dose during the cancer operation - so in most patients no visits to the radiotherapy department are required. This is especially relevant during the COVID-19 pandemic. When the radiotherapy is completed during the cancer operation, under the same anaesthetic, it greatly reduces the need for repeated post-operative visits to the hospital for postoperative external beam whole radiotherapy which are necessary for regimens such as Fast Forward or IMPORT-Low
This is why it has been included in several national and interantional guidelines for treatment of breast cancer during the COVID-19 pandemic caused by the widespread infection with the SARS-CoV-2 virus
During the COVID-19 pandemic, new guidelines for treatment of beast cancer and radiotherapy have recommend using TARGIT-IORT because it would save patients the daily travel (and viral exposure) to radiotherapy departments:
Global radiation oncology's targeted preparedness for COVID-19
“where the technology is available the use of IORT may obviate the need for any further outpatient treatment and should be considered an option ..”
British Association of Cancer Surgery (BASO~ACS) https://baso.org.uk/media/98159/covid_19_and_breast_cancer_march_2020.pdf
German University Hospitals
Italian Association of Radiotherapy and Clinical Oncology
China is increasing its use of TARGIT-IORT #breastcancer by equipping more centres with the TARGIT-IORT equipment
Click here to see the national and international guidelines recommending TARGIT-IORT for breast cancer
Information about Intrabeam TARGIT IORT
Intrabeam TARGIT IORT for breast cancer is clinically effective - confirmed in the TARGIT-A international clinical trial
First publication of the main results (2010)
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
5-year results and first analysis of survival (2014)
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.
Full 226 page report of the TARGIT-A trial of Intrabeam TARGIT IORT for HTA, NIHR, Department of Health, UK (2016)
An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial).
Recent peer reviewed publications are below: more are available here